Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation
- PMID: 36211358
- PMCID: PMC9537469
- DOI: 10.3389/fimmu.2022.971156
Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation
Abstract
Cytomegalovirus (CMV) infection remains a frequent complication after hematopoietic stem cell transplantation (HSCT) and causes significant morbidity and mortality in transplantation recipients. In this review, we highlight the role of major risk factors that are associated with the incidence of CMV infection. Advances in immunosurveillance may predict CMV infection, allowing early interventions to prevent severe infection. Furthermore, numerous therapeutic strategies against CMV infection after HSCT are summarized. A comprehensive understanding of the current situation of CMV treatment may provide a hint for clinical practice and even promote the development of novel strategies for precision medicine.
Keywords: CMV; HSCT; diagnosis; immune recovery; treatment.
Copyright © 2022 Cui, Zhao, Sun, Wen, Zhang, Li and Long.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Ljungman P, Camara R, Robin C, Crocchiolo R, Einsele H, Hill J A, et al. . Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis (2019) 19(8):e260–72. doi: 10.1016/S1473-3099(19)30107-0 - DOI - PubMed
